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Importance: The absence of data on the prevalence of
pilomatricoma among patients with Turner syndrome
served as the catalyst for this multicenter investigation.
Objectives: To ascertain the prevalence of pilomatri-
coma among patients with Turner syndrome and to de-
termine any association between the development of pi-
lomatricomas and the use of exogenous hormones in
patients with Turner syndrome.
Design: A retrospective medical record review from Janu-
ary 1, 2000, through January 1, 2010, was performed of
all patients with Turner syndrome. Data on pilomatri-
comas and the use of hormone therapy were collected.
Setting: University of California–Davis Medical Cen-
ter, University of Nebraska Medical Center, and The Uni-
versity of North Carolina at Chapel Hill.
Participants: Patients with a diagnosis of Turner syn-
drome.
Main Outcome Measures: Prevalence of concomi-
tant pilomatricoma and diagnosis of Turner syndrome.
Secondary outcome measures included the use of the ex-
ogenous hormones estrogen or recombinant human
growth hormone (rhGH).
Results: In total, 311 patients with Turner syndrome were
identified from these 3 institutions. Among them, 8 pa-
tients (2.6%) were diagnosed as having pilomatricomas.
Before the development of pilomatricomas, 5 patients had
been treated with rhGH but not estrogen, 1 patient had
received estrogen but not rhGH, and 2 patients did not
receive either therapy.
Conclusions and Relevance: Although the preva-
lence of pilomatricoma among the general population is
unknown, this study demonstrates a high prevalence
(2.6%) of pilomatricomas among patients with Turner
syndrome. No apparent relationship was noted among
our patients or in the literature between the use of rhGH
and the development of pilomatricomas.
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P ILOMATRICOMAS (ALSO KNOWNas calcifying epithelioma, be-nign calcifying epithelioma ofMalherbe, and piloma-trixoma) are benign cutane-
ous adnexal tumors that arise from the outer
root sheath cells in the hair follicle.1-3 These
tumors have a 3:2 female predominance,
with most manifesting on the head, neck,
and upper extremities before age 20 years.4-8
The prevalence of pilomatricoma
among the general population is un-
known. Pilomatricomas typically appear
as solitary, hard, mobile, nontender nod-
ules, with bluish discoloration2 , 4 , 9
(Figure 1 and Figure 2). Classic histo-
logical findings may include central
“shadow cells” surrounded by basophilic
cells, as well as calcification5 (Figure 3
and Figure 4). Surgical excision re-
mains the standard of care, and recur-
rence rates are between 0% and 6%.2,10 Case
series in the 1960s and 1970s reported that
97% of the lesions occurred in individu-
als of white race/ethnicity, but cases have
since been published among individuals
of black, Hispanic, and Asian races/
ethnicities.9,11,12
Turner syndrome, first described by
Henry Turner in 1938, has an incidence
of 1 in 2500 live female births and is the
most common sex chromosomal abnor-
mality affecting girls and women.13-15 By
definition, individuals with Turner syn-
drome are female and lack part or all of
the second sex chromosome. Many pa-
tients have classic 45,X karyotypes, but fre-
quently patients have another cell line con-
taining 2 normal Xs or a normal X and a
structurally abnormal X or Y chromo-
some.16 More than 90% of patients with
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fest premature ovarian failure, and are at high risk for vari-
ous phenotypic abnormalities (eg, high palate, nail dys-
plasia, low posterior hairline, widely spaced nipples, webbed
neck, and low-set or malrotated ears), as well as other medi-
cal problems such as cardiovascular defects, skeletal anoma-
lies, and autoimmune disorders.17 Patients with Turner syn-
drome frequently are prescribed recombinant human
growth hormone (rhGH) therapy to increase their growth
velocity and final adult height. Those who fail to undergo
pubertyorwhodevelopprematureovarian failureare treated
with estrogen.
Four case reports have described the initial develop-
ment of pilomatricomas between the ages of 6 and 23 years
in patients with Turner syndrome.18-20 Three of the 4 pa-
tients had multiple lesions or recurrences, with 10 le-
sions developing over 7 years in 1 patient. Only 1 pa-
tient had reported the use of rhGH and estrogen, both
before the lesion appeared. The absence of data on the
prevalence of pilomatricoma among patients with Turner
syndrome served as the catalyst for this multicenter
investigation.
We performed a retrospective study of patients with
Turner syndrome treated at University of California–
Davis Medical Center, University of Nebraska Medical
Center, and The University of North Carolina at Chapel
Hill to ascertain the prevalence of pilomatricoma among
patients with Turner syndrome. We also evaluated for
any association between the development of pilomatri-
comas and the use of exogenous hormones in patients
with Turner syndrome.
METHODS
The study was approved by the institutional review boards at
University of California–Davis Medical Center, University of
Nebraska Medical Center, and The University of North Caro-
lina at Chapel Hill. The medical record databases were ini-
tially searched for International Classification of Diseases, Ninth
Revision diagnoses of Turner syndrome and gonadal dysgen-
esis; Turner syndrome characterizes most of those with an In-
ternational Classification of Diseases, Ninth Revision diagnosis
of gonadal dysgenesis. The medical records were manually and
individually reviewed to ensure the accuracy of the diagnosis
Figure 3. Sharply demarcated pilomatricoma tumor surrounded by a fibrous
capsule (hematoxylin-eosin, original magnification ×5). Reproduced with
permission from Maxwell Fung, MD.
Figure 4. Pilomatricoma showing darkly stained basophilic calcium and
shadow cells with missing nuclei (hematoxylin-eosin, original magnification
×40). Reproduced with permission from Maxwell Fung, MD.
Figure 1. Child with pilomatricoma on the nose.
Figure 2. Pilomatricoma lesion on the lateral aspect of the bicep.
JAMA DERMATOL/ VOL 149 (NO. 5), MAY 2013 WWW.JAMADERM.COM
560
©2013 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
of Turner syndrome. Patients were included if they had Turner
syndrome and were seen by a health care provider between Janu-
ary 1, 2000, and January 1, 2010. The data collected included
age, karyotype, pilomatricomas, and hormonal treatment with
rhGH, estrogen, or both.
RESULTS
In total, 311 patients with Turner syndrome were identi-
fied from the combined data at 3 institutions from Janu-
ary 1, 2000, through January 1, 2010. The mean (SD) age
of patients with Turner syndrome was 14.0 (10.2) years.
Of the known karyotypes, 119 (38.3%) were monosomy
45,X. Of 311 patients, 201 (64.6%) had received rhGH and
153 (49.2%) had received estrogen. Only 96 patients
(30.8%) had received both rhGH and estrogen, while 61
patients (19.6%) did not receive either therapy.
Eight of 311 patients (2.6%) were diagnosed as hav-
ing pilomatricomas (case reports and Table). The mean
(SD) age at initial pilomatricoma diagnosis was 7.0 (3.9)
years (age range, 3-15 years). Four of 8 patients devel-
oped multiple pilomatricomas. Evaluation of karyo-
types among the 8 revealed 3 to be monosomic 45,X. Two
patients had Y chromosome material, both Y isochro-
mosomes, 45,X/46,X,idic(Y) in one patient and 45,X/
46,X,idic(Y)/47,X,idic(Y),idic(Y) in the other patient.
Of 8 patients with Turner syndrome, 5 had been treated
with rhGH but not estrogen. One patient had received
estrogen but not rhGH. Two patients did not receive either
therapy.
In each case, the lesions were biopsied or excised. The
diagnosis of pilomatricoma was pathologically confirmed.
CASE REPORTS
Patient 1
A 5-year-old girl of white race/ethnicity with 45,X Turner
syndrome diagnosed at birth owing to lymphedema and
coarctation of the aorta developed a 20-mm tender, non-
pruritic, firm, mobile, bluish subcutaneous nodule on her
right upper back over several months. She had begun
rhGH treatment at age 3 years 1 month, 2 years 4 months
before being seen with pilomatricoma.
Patient 2
A 15-year-old girl of white race/ethnicity with 45,X/
46,X,idic(X) Turner syndrome developed a nodule over
the eyebrow. The patient had noted the firm mass 8
months previously and stated that it had grown rapidly
to its current 3-mm diameter. On examination, it was firm,
mobile, and nontender with a dark discoloration. She had
been started on conjugated estrogens 6 months before
presentation but had not received rhGH therapy.
Patient 3
A 24-year-old woman of white race/ethnicity with 45,X
Turner syndrome, hypothyroidism, obesity, multiple be-

















45,X 4 (9.3) 18 (24.7) 97 (49.7) 119 (38.3)
45,X/46,XX 1 (2.3) 8 (11.0) 20 (10.3) 29 (9.3)
45,X/46,X,idic(X)a 4 (9.3) 8 (11.0) 13 (6.6) 25 (8.0)
45,X/ring(X) 1 (2.3) 2 (2.7) 18 (9.2) 21 (6.8)
Other 8 (18.6) 9 (12.3) 35 (17.9) 52 (16.7)
Unknown 25 (58.1) 28 (38.9) 12 (6.2) 65 (20.9)
Age, y
Mean (SD) 10.5 (5.7) 20.5 (15.1) 12.4 (7.6) 14.0 (10.2)
Median 11 18 12 13
At initial pilomatricoma diagnosisb NA 5, 15 3, 4, 4, 5, 7, 10 NA
Hormonal Treatment With rhGH, Estrogen, or Both, No. (%)
rhGH
Received medication 35 (81.4) 30 (41.1) 136 (69.7) 201 (64.6)
Did not receive medication 7 (16.3) 26 (35.6) 56 (28.7) 89 (28.6)
Unknown 1 (2.3) 17 (23.3) 3 (1.5) 21 (6.8)
Estrogen
Received medication 15 (34.9) 41 (56.2) 97 (49.7) 153 (49.2)
Did not receive medication 21 (48.8) 22 (30.1) 98 (50.3) 141 (45.3)
Unknown 7 (16.3) 10 (14.0) 0 17 (5.5)
rhGH and estrogen
Received both medications 11 (25.6) 19 (26.0) 66 (33.8) 96 (30.9)
Did not receive either medication 4 (9.3) 14 (19.2) 43 (22.1) 61 (19.6)
Abbreviations: NA, not applicable; rhGH, recombinant human growth hormone.
a Isochromosomes include isocentric, dicentric, and pseudodicentric chromosomes.
bAmong 8 patients with pilomatricomas.
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nign nevi, chronic lymphedema, and a repaired coarc-
tation of the aorta was seen at the clinic with 2 hard, ten-
der nodules. She had a history of 14 pilomatricomas
removed, the first 2 at age 3 years above the left eye and
cheek. The recent nodules were tender and firm, one of
12-mm diameter on the posterior scalp and the other a
10-mm nodule on the left arm. She had used rhGH be-
tween the ages of 7 and 14 years and was taking oral con-
traceptive pills.
Patient 4
A 16-year-old girl of white race/ethnicity with 45,X Turner
syndrome was seen with a slowly enlarging 9  9-mm
bluish papule on the center of her forehead. She had a
history of 6 excised pilomatricomas since age 7 years. Her
dermatologic history also included recurrent verruca vul-
garis on the hands and feet and removal of 3 compound
nevi. The forehead lesion was monitored and under-
went spontaneous regression. The patient had used rhGH
between the ages of 21⁄2 and 14 years, and she had never
received estrogen therapy.
Patient 5
An 11-year-old girl of Hispanic race/ethnicity with Turner
syndrome, in good health and taking no medications, was
seen with two 3-mm asymptomatic nodules on the fore-
head and the right cheek. Her medical history was signifi-
cant for having had 2 pilomatricomas removed at age 5
years and 3 removed at age 8 years. Owing to the mul-
tiple pilomatricomas, a karyotype was obtained at age 8
years, revealing 46,X,del(X)(p11.22) Turner syndrome.
Dermatologic examination was also significant for kera-
tosis pilaris and multiple telangiectatic macules 2 to 5 mm
in diameter on the upper extremities. The patient’s nod-
ules were asymptomatic and were regularly monitored. The
patient had not been receiving rhGH or estrogen.
Patient 6
A 9-year-old girl of white race/ethnicity diagnosed as hav-
ing 45,X/46,X,idic(Y)(p11.3)/47,X,idic(Y)(p11.3),idic
(Y)(p11.3) Turner syndrome at age 2 years was seen with
an 11-mm nodule on the neck. Her medical history was
significant for a 3  5-mm pilomatricoma removed at age
7 years from below her left eyelid, gonadectomy at age 3
years, and treated hypothyroidism. Physical examina-
tion revealed keratosis pilaris, sebopsoriasis, and 2 café
au lait macules on the trunk and 2 on the lower extremi-
ties, as well as a large lightly hyperpigmented patch on
the posterior right lower extremity. The patient had 10
nevi on the body, with acanthosis nigricans around the
posterior neck. The neck nodule was excised, and patho-
logical examination confirmed pilomatricoma. Since age
4 years, she had been treated with rhGH but had not re-
ceived estrogen.
Patient 7
A 10-year-old girl of Hispanic race/ethnicity with 45,X/
46,X,ring(X) Turner syndrome diagnosed at age 15 months
because of gross motor delays was seen at the dermatol-
ogy clinic for treatment of eczema and a nodule of less than
20-mm diameter on her face. The lesion was biopsied, and
pathological examination confirmed the diagnosis of pi-
lomatricoma. At that time, no excision was performed.
Treatment with rhGH had begun at age 2 years 7 months.
She had not received estrogen therapy.
Patient 8
A 4-year-old girl of white race/ethnicity with 45,X/
46,X,psudic(Y)(p11.3) Turner syndrome was seen at the
dermatology clinic with a nodule on her face. Her medi-
cal history included a horseshoe kidney, mild learning dis-
ability, and hypothyroidism. She had received rhGH for 2
months before presentation. The excised nodule was di-
agnosed as a pilomatricoma by pathological examination.
COMMENT
Within the cohort of 311 patients with Turner syn-
drome, 8 individuals developed at least 1 pilomatri-
coma, for a prevalence of 2.6%. The lack of pilomatri-
coma prevalence data among the general population
prevents comparison with the prevalence among our co-
hort with Turner syndrome. In this study, patients with
Turner syndrome developed pilomatricomas at a mean
(SD) age of 7.0 (3.9) years, and most occurred on the head
and neck. These findings are consistent with previous stud-
ies4-6 of pilomatricoma sites and age at onset. The inci-
dence of pilomatricoma was also examined in our cohort
with Turner syndrome. During the observation period, the
patients were followed up for 2634 patient-years, and 6
patients developed their first pilomatricoma, resulting in
an incidence of 0.0022 cases per year. Unfortunately, the
published data on the general population are limited to
pathology reports of excised skin lesions, with a reported
0.12% case incidence per 35 years, or 0.000035 cases per
year.4 The methods used to determine incidence in this
study differ, so comparisons are indirect.4
It has been hypothesized that growth hormone (or its
effector molecule insulinlike growth factor 1) and estro-
gen may promote hair follicle growth, inhibit apoptosis,
and produce pilomatricomas.20-22 Although both rhGH and
estrogen can promote tumor growth, there does not seem
to be an association between their use and the develop-
ment of pilomatricomas; 5 of 8 patients (62.5%)with pi-
lomatricomas herein had received rhGH, which is com-
parable to the 64.6% who had received rhGH in our overall
cohort with Turner syndrome. None of those with pilom-
atricomas had received estrogen therapy before the devel-
opment of their first pilomatricoma.
Possible explanations for the increased prevalence of
pilomatricoma among patients with Turner syndrome in-
clude effects from haploinsufficiency of gene expres-
sion in pseudoautosomal regions and mutations or im-
printing on the X chromosome. A mouse model of Turner
syndrome demonstrated a reduction of Gp3 (GPC3 in
humans).23 Low GPC3 levels result in increases of the
transcription factor -catenin.24,25 Increased -catenin is
associated with decreased apoptosis and increased hair
JAMA DERMATOL/ VOL 149 (NO. 5), MAY 2013 WWW.JAMADERM.COM
562
©2013 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Non-Human Traffic (NHT) User  on 02/02/2021
follicle differentiation.26 Error in expression of -catenin
(encoded by CTNNB1) has been attributed to pilomatri-
comas27 and may lead to the development of pilomatri-
comas in other genetic disorders such as Gardner syn-
drome,28 myotonic dystrophy,29 Rubinstein-Taybi
syndrome,30 cerebral gigantism,31 Kabuki syndrome,32 glio-
matosis cerebri,33 glioblastoma,34 and trisomy 9.35-37 There
may be an association between an upstream event that
causes increased -catenin expression and subsequent
development of pilomatricomas.
Multiple studies38-43 have reported tumor formation
in individuals with Turner syndrome. Cohort stud-
ies44-46 have demonstrated an increase in site-specific can-
cers above that among the general population. Girls and
women with Y chromosome material have a 25% to 43%
chance of developing gonadoblastomas, while those with-
out Y chromosome material are not at risk.47-50 Notably,
2 of 8 patients herein with pilomatricomas had karyo-
types containing Y chromosome material, whereas in the
overall cohort with Turner syndrome, only 18 of 311 pa-
tients (5.8%) had Y chromosome material. Whether there
is an association between Y chromosome material and
the development of pilomatricomas is unknown. Pa-
tients with Turner syndrome may have an increased risk
for cancers of the colon or rectum,44,45 as well as menin-
geal tumors, childhood brain tumors, and bladder and
urethral cancer.46 Individuals with chromosomal aber-
ration are at increased risk for tumors. This may be due
to a tendency for mitotic nondisjunction that may un-
derlie the development of cancers.51
Our study has several limitations. The current preva-
lence rate of pilomatricoma is unknown for the general
population. As a result, we can only speculate that the preva-
lence of 2.6% among patients with Turner syndrome is
greater than that among the general population. There are
limitations of medical record review; the number of le-
sions may be underreported because of the potential lack
of accurate documentation of lesions on examination and
the inability to access records of unaffiliated health care pro-
viders. Some patients may have had lesions that were un-
diagnosed, undocumented, or unevaluated by a patholo-
gist. Given the predominance of pilomatricomas among girls
younger than 20 years, it is possible that some of the effect
is related to epidemiological factors that have yet to be ex-
plained, rather than being explained fully by factors re-
lated to Turner syndrome.
Physicians caring for patients with Turner syndrome
should be aware of the prevalence of pilomatricoma among
this population. Those treating Turner syndrome should
suspect pilomatricoma in patients seen with solitary, hard,
mobile, nontender, bluish nodular growths on the head
and neck.
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